source
- Amgen's Dazodalibep Shows Positive Results in First Phase 3 Trial for Sjögren’s SyndromeAmgen announced that its experimental drug dazodalibep, acquired through the Horizon Therapeutics acquisition, met the primary endpoint in the first of two Phase 3 trials for Sjögren’s syndrome, a…
- Celldex shares drop as Phase 3 data for barzolvolimab show efficacy but raise anaphylaxis safety concernsCelldex reported Phase 3 results for barzolvolimab in chronic spontaneous urticaria, showing strong efficacy against hives and itching. Two cases of life-threatening anaphylaxis were observed amon…